Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18 (PDF)
(Sprache: Englisch)
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming...
sofort als Download lieferbar
Printausgabe 106.99 €
eBook (pdf) -10%
96.29 €
48 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18 (PDF)“
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Autoren-Porträt
Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.
Bibliographische Angaben
- 2018, 1st ed. 2018, 158 Seiten, Englisch
- Herausgegeben: Makoto Hosono, Jean-François Chatal
- Verlag: Springer-Verlag GmbH
- ISBN-10: 331978238X
- ISBN-13: 9783319782386
- Erscheinungsdatum: 24.04.2018
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Größe: 3.22 MB
- Ohne Kopierschutz
- Vorlesefunktion
Sprache:
Englisch
Kommentar zu "Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18"
0 Gebrauchte Artikel zu „Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Resistance to Ibritumomab in Lymphoma / Resistance to Targeted Anti-Cancer Therapeutics Bd.18".
Kommentar verfassen